Chronos Archive seal
The Human Record

Wilma Rudolph

Case HR-ML036 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
June 23, 1940 – November 12, 1994
Synthetic DOB
1972-06-23
Index visit
2026-06-29 at age 54
Synthetic MRN
HR-ML036-SYN

Teaching objective: Recognize new progressive neurologic symptoms (morning headache, word-finding pauses and a clumsy hand) as a reason for prompt contrast MRI of the brain in a 54-year-old Black woman who survived childhood polio, and then manage a newly diagnosed glioblastoma to current standards: dexamethasone only for symptomatic edema, at the lowest dose and tapered early, with glucose and stomach protection; no seizure prophylaxis when no seizure has occurred; CT to exclude another primary; awake craniotomy with language and motor mapping for maximal safe resection and an MRI within 48 hours; the WHO CNS5 2021 integrated diagnosis with IDH, TERT, EGFR, chromosome 7 and 10 and MGMT promoter methylation; radiotherapy 60 Gy in 30 fractions with daily temozolomide and Pneumocystis prophylaxis, then adjuvant temozolomide with tumor-treating fields; blood count and liver test monitoring; RANO 2.0 response assessment that allows for pseudoprogression; venous thromboembolism awareness; fall prevention for a woman whose new right-sided weakness meets a left leg weakened by polio in childhood; and early palliative care with advance care planning alongside treatment, on the NCCN CNS cancers guideline, the EANO 2021 diffuse glioma guideline and the ASCO-SNO glioma guideline. Her childhood care, given at a Black medical school because care nearer home was not offered to her, frames the commitment to equal access to a brain tumor center and clinical trials.

Historical timeline

DateEventClaims
June 23, 1940Born prematurely in Saint Bethlehem, near Clarksville, Tennessee, weighing about 4.5 pounds.CLM-0001, CLM-0002
about 1944Double pneumonia and scarlet fever at about four; polio in early childhood leaves the left leg partly paralyzed.CLM-0003, CLM-0004
about 1946Wears a metal leg brace and special shoe; weekly treatment at Meharry Medical College in Nashville, with massage at home.CLM-0005
about 1952Walks without the brace by about twelve, after taking it off in public at about nine and a half.CLM-0006
1956Wins a bronze medal in the 4 x 100-meter relay at the Melbourne Olympics, at sixteen.CLM-0007
1960Wins three gold medals at the Rome Olympics: 100 meters, 200 meters and the 4 x 100-meter relay.CLM-0007
1992Returns to Tennessee as a vice president of a Nashville hospital.CLM-0008
November 12, 1994Dies of brain cancer at her home in Brentwood, Tennessee, at 54, after a diagnosis earlier that year, reported shortly after her mother's death.CLM-0009, CLM-0010

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Wilma Glodean Rudolph was born on June 23, 1940, in Saint Bethlehem, Tennessee, near Clarksville, the twentieth of twenty-two children in her father's family. She grew up in a large, poor Black family in the segregated South. confirmed Wilma Rudolph (Olympedia athlete profile) supports
Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports
Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports
Norwood A. Wilma Rudolph supports
Former Olympic sprinter Wilma Rudolph dies at 54 supports
HISTMED Master Roster v3 context
D She was born prematurely and weighed about 4.5 pounds at birth.
Low birth weight is part of her early medical history; it carries no specific risk for the modern episode.
confirmed Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports
Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia supports
D She was often ill as a small child: at about age four she had double pneumonia followed by scarlet fever, and she had a number of other childhood illnesses before polio. confirmed Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports
Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia supports
Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports
Norwood A. Wilma Rudolph supports
D In early childhood she had polio, which left her left leg paralyzed or partly paralyzed, with the foot turned inward. Sources give her age at the illness as an infant, about four, or about five.
The documented polio is recorded as late effects of poliomyelitis in the past medical history and on the problem list, and the modern episode treats the once-weak left leg as a factor in mobility and falls.
confirmed Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports
Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia supports
Wilma Rudolph (Olympedia athlete profile) supports
Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports
D She wore a metal leg brace for several years (from about age six to ten in one account) and a specially made shoe. Once a week her mother took her by bus to Nashville, a 90-minute round trip, to the closest doctors who would treat her in the segregated South: physicians at Meharry Medical College, a historically Black medical school, fitted the brace and prescribed massage and heat. At home her family massaged the leg several times a day.
Anchors the modern equity teaching: as a child she had to travel to a Black medical school for care that was not offered to her nearer home.
confirmed Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports
Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia supports
Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports
Norwood A. Wilma Rudolph supports
D She later wrote that a doctor told her she would never walk again, and that her mother told her she would. Accounts of her recovery differ: she took the brace off in public at about nine and a half, could move about with the brace by eight, was running by eleven, and no longer needed the brace by about twelve. confirmed Norwood A. Wilma Rudolph supports
Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports
Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia supports
Former Olympic sprinter Wilma Rudolph dies at 54 supports
D At sixteen she won a bronze medal in the 4 x 100-meter relay at the 1956 Olympic Games in Melbourne. At the 1960 Games in Rome she won gold in the 100 meters, the 200 meters and the 4 x 100-meter relay, the first American woman to win three gold medals in track and field at one Olympics. She ran for the Tennessee State University Tigerbelles.
Her athletic career anchors the modern social history and the strength of the once-weak left leg.
confirmed Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports
Wilma Rudolph (Olympedia athlete profile) supports
Norwood A. Wilma Rudolph supports
Former Olympic sprinter Wilma Rudolph dies at 54 supports
Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports
D After retiring from competition she worked in teaching, coaching and community work, founded an organization to help amateur track and field athletes, and in 1992 returned to Tennessee as a vice president of a Nashville hospital.
Anchors the modern social history.
confirmed Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports
Norwood A. Wilma Rudolph supports
D In 1994, shortly after her mother's death, she was diagnosed with brain cancer; two accounts add throat cancer. Afterwards she seldom appeared in public, and she was in and out of hospitals for more than five months as the cancer spread.
The anchor for the modern episode. The type, location and treatment of her brain cancer were not made public; the throat cancer is reported without detail and is not used.
confirmed Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports
Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) supports
Former Olympic sprinter Wilma Rudolph dies at 54 supports
D She died of brain cancer at her home in Brentwood, Tennessee, on November 12, 1994, at 54.
The documented disease to which the synthetic diagnosis is linked. History only, stated without detail.
confirmed Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia supports
Wilma Rudolph (Olympedia athlete profile) supports
Former Olympic sprinter Wilma Rudolph dies at 54 supports
Norwood A. Wilma Rudolph supports
Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Three weeks of headaches on waking, with ten days of pauses in finding words and clumsiness of the right hand, in a previously well woman of 54: an intracranial lesion must be excluded. MRI of the brain with and without contrast booked for tomorrow morning, and neuro-oncology review booked resolved confirmed active
S Left posterior frontal ring-enhancing mass, 3.8 cm, with central necrosis, surrounding edema and 5 mm midline shift, next to the language and motor areas; presumed high-grade glioma, with no primary cancer elsewhere on CT; tissue diagnosis pending resolved confirmed active CLM-0009
S Glioblastoma, IDH-wildtype, CNS WHO grade 4, left posterior frontal lobe, MGMT promoter methylated, after gross total resection of the enhancing tumor; synthetic modern detail linked to her publicly reported brain cancer active confirmed both_with_link CLM-0009, CLM-0010
S Late effects of childhood poliomyelitis: paralysis of the left leg in early childhood, treated with a metal brace, a special shoe, massage and heat, with full recovery of walking by about age 12 and a later career as an Olympic sprinter; no new weakness, fatigue or pain now to suggest post-polio syndrome active confirmed both_with_link CLM-0003, CLM-0004, CLM-0005, CLM-0006
S Vasogenic cerebral edema around the left frontal mass, with 5 mm midline shift, causing headache and contributing to the language and right-hand symptoms; treated with dexamethasone resolved confirmed active
S Steroid-induced hyperglycemia on dexamethasone: random glucose 168 mg/dL, with an A1c of 5.6% before steroids resolved confirmed active
S Lymphopenia from temozolomide, grade 2 (absolute lymphocytes 0.5 x 10^3/uL at the end of chemoradiation): Pneumocystis prophylaxis continues until recovery to grade 1 or better active confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-06-29 Hemoglobin [Mass/volume] in Blood 13.1 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-06-29 Leukocytes [#/volume] in Blood by Automated count 7.1 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-06-29 Platelets [#/volume] in Blood by Automated count 262 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-06-29 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-06-29 Potassium [Moles/volume] in Serum or Plasma 4.2 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-06-29 Creatinine [Mass/volume] in Serum or Plasma 0.86 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-06-29 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 80 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-06-29 Glucose [Mass/volume] in Serum or Plasma 92 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-06-29 Hemoglobin A1c/Hemoglobin.total in Blood 5.6%
Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes
http://loinc.org · 4548-4
S 2026-06-29 Karnofsky Performance Status score 80 http://loinc.org · 89243-0
S 2026-06-29 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 2026-07-02 Hemoglobin [Mass/volume] in Blood 13 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-07-02 Leukocytes [#/volume] in Blood by Automated count 11.8 10*3/uL (high)
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-07-02 Platelets [#/volume] in Blood by Automated count 270 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-07-02 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-07-02 Potassium [Moles/volume] in Serum or Plasma 4 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-07-02 Creatinine [Mass/volume] in Serum or Plasma 0.84 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-07-02 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 83 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-07-02 Glucose [Mass/volume] in Serum or Plasma 138 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-07-02 INR in Platelet poor plasma by Coagulation assay 1
Reference 0.9-1.1
http://loinc.org · 6301-6
S 2026-07-02 aPTT in Blood by Coagulation assay 29 s
Reference 25-37 s
http://loinc.org · 3173-2
S 2026-07-02 Karnofsky Performance Status score 80 http://loinc.org · 89243-0
S 2026-07-02 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 7 http://loinc.org · 44261-6
S 2026-07-02 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 9 http://loinc.org · 70274-6
S 2026-07-29 Hemoglobin [Mass/volume] in Blood 12.6 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-07-29 Leukocytes [#/volume] in Blood by Automated count 9.6 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-07-29 Neutrophils [#/volume] in Blood by Automated count 7.2 10*3/uL
Reference 1.5-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-07-29 Lymphocytes [#/volume] in Blood by Automated count 1.1 10*3/uL
Reference 1-4 10*3/uL
http://loinc.org · 731-0
S 2026-07-29 Platelets [#/volume] in Blood by Automated count 248 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-07-29 Creatinine [Mass/volume] in Serum or Plasma 0.82 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-07-29 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 85 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-07-29 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-07-29 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-07-29 Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-07-29 Albumin [Mass/volume] in Serum or Plasma 4 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-07-29 Glucose [Mass/volume] in Serum or Plasma 168 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-07-29 Karnofsky Performance Status score 90 http://loinc.org · 89243-0
S 2026-07-29 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 http://loinc.org · 44261-6
S 2026-09-14 Hemoglobin [Mass/volume] in Blood 11.9 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-09-14 Leukocytes [#/volume] in Blood by Automated count 3.6 10*3/uL (low)
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-09-14 Neutrophils [#/volume] in Blood by Automated count 2.4 10*3/uL
Reference 1.5-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-09-14 Lymphocytes [#/volume] in Blood by Automated count 0.5 10*3/uL (low)
Reference 1-4 10*3/uL
http://loinc.org · 731-0
S 2026-09-14 Platelets [#/volume] in Blood by Automated count 112 10*3/uL (low)
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-09-14 Creatinine [Mass/volume] in Serum or Plasma 0.8 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-09-14 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 88 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-09-14 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 48 U/L (high)
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-09-14 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 39 U/L (high)
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-09-14 Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-09-14 Glucose [Mass/volume] in Serum or Plasma 96 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-09-14 Karnofsky Performance Status score 80 http://loinc.org · 89243-0
S 2026-09-14 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 8 http://loinc.org · 44261-6
S 2026-10-09 Hemoglobin [Mass/volume] in Blood 12.2 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-10-09 Leukocytes [#/volume] in Blood by Automated count 4.4 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-10-09 Neutrophils [#/volume] in Blood by Automated count 2.9 10*3/uL
Reference 1.5-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-10-09 Lymphocytes [#/volume] in Blood by Automated count 0.6 10*3/uL (low)
Reference 1-4 10*3/uL
http://loinc.org · 731-0
S 2026-10-09 Platelets [#/volume] in Blood by Automated count 168 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-10-09 Creatinine [Mass/volume] in Serum or Plasma 0.81 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-10-09 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 86 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-10-09 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-10-09 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-10-09 Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-10-09 Glucose [Mass/volume] in Serum or Plasma 91 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-10-09 Karnofsky Performance Status score 80 http://loinc.org · 89243-0
S 2026-10-09 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 http://loinc.org · 44261-6
S 2026-10-29 Hemoglobin [Mass/volume] in Blood 11.8 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-10-29 Leukocytes [#/volume] in Blood by Automated count 3.4 10*3/uL (low)
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-10-29 Neutrophils [#/volume] in Blood by Automated count 1.9 10*3/uL
Reference 1.5-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-10-29 Lymphocytes [#/volume] in Blood by Automated count 0.6 10*3/uL (low)
Reference 1-4 10*3/uL
http://loinc.org · 731-0
S 2026-10-29 Platelets [#/volume] in Blood by Automated count 121 10*3/uL (low)
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-10-29 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 33 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-10-29 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-10-29 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-06-29Body height180 cm8302-2S
2026-06-29Body weight68 kg29463-7S
2026-06-29Body mass index (BMI) [Ratio]21 kg/m239156-5S
2026-06-29Systolic blood pressure126 mm[Hg]8480-6S
2026-06-29Diastolic blood pressure78 mm[Hg]8462-4S
2026-06-29Heart rate72 /min8867-4S
2026-06-29Respiratory rate14 /min9279-1S
2026-06-29Body temperature36.7 Cel8310-5S
2026-06-29Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-07-02Body height180 cm8302-2S
2026-07-02Body weight67.8 kg29463-7S
2026-07-02Body mass index (BMI) [Ratio]20.9 kg/m239156-5S
2026-07-02Systolic blood pressure134 mm[Hg]8480-6S
2026-07-02Diastolic blood pressure82 mm[Hg]8462-4S
2026-07-02Heart rate78 /min8867-4S
2026-07-02Respiratory rate14 /min9279-1S
2026-07-02Body temperature36.6 Cel8310-5S
2026-07-02Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-07-29Body height180 cm8302-2S
2026-07-29Body weight69.4 kg29463-7S
2026-07-29Body mass index (BMI) [Ratio]21.4 kg/m239156-5S
2026-07-29Systolic blood pressure132 mm[Hg]8480-6S
2026-07-29Diastolic blood pressure80 mm[Hg]8462-4S
2026-07-29Heart rate76 /min8867-4S
2026-07-29Respiratory rate14 /min9279-1S
2026-07-29Body temperature36.6 Cel8310-5S
2026-07-29Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-09-14Body height180 cm8302-2S
2026-09-14Body weight67.2 kg29463-7S
2026-09-14Body mass index (BMI) [Ratio]20.7 kg/m239156-5S
2026-09-14Systolic blood pressure118 mm[Hg]8480-6S
2026-09-14Diastolic blood pressure74 mm[Hg]8462-4S
2026-09-14Heart rate80 /min8867-4S
2026-09-14Respiratory rate16 /min9279-1S
2026-09-14Body temperature36.8 Cel8310-5S
2026-09-14Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-10-09Body height180 cm8302-2S
2026-10-09Body weight66.6 kg29463-7S
2026-10-09Body mass index (BMI) [Ratio]20.6 kg/m239156-5S
2026-10-09Systolic blood pressure120 mm[Hg]8480-6S
2026-10-09Diastolic blood pressure76 mm[Hg]8462-4S
2026-10-09Heart rate74 /min8867-4S
2026-10-09Respiratory rate14 /min9279-1S
2026-10-09Body temperature36.6 Cel8310-5S
2026-10-09Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-10-29Body height180 cm8302-2S
2026-10-29Body weight66.9 kg29463-7S
2026-10-29Body mass index (BMI) [Ratio]20.6 kg/m239156-5S
2026-10-29Systolic blood pressure118 mm[Hg]8480-6S
2026-10-29Diastolic blood pressure72 mm[Hg]8462-4S
2026-10-29Heart rate76 /min8867-4S
2026-10-29Respiratory rate14 /min9279-1S
2026-10-29Body temperature36.5 Cel8310-5S
2026-10-29Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

Care-plan goals

GoalTarget dateStatusOutcome
MRI of the brain within 24 hours and a neuro-oncology and neurosurgery plan within one week of presentation2026-07-02completedMRI the next morning; consultation three days after the first visit
Maximal safe resection within two weeks of the MRI, preserving language and right-hand strength2026-07-29completedGross total resection of the enhancing tumor nine days after the first visit; speech back to normal within days and right-hand strength nearly normal
Radiotherapy with daily temozolomide started within six weeks of surgery and completed on schedule2026-09-14completedStarted 26 days after surgery; 30 fractions and 42 days of temozolomide completed without a break
Dexamethasone tapered off within five weeks of surgery, with glucose back to normal2026-09-14completedOff dexamethasone five weeks after surgery; glucose 96 mg/dL afterwards
No falls, and walking independently, through treatment2026-10-09completedNo falls; walks independently, with a cane only on uneven ground; home exercise program continued
Palliative care involved and her wishes recorded before adjuvant treatment begins2026-10-09completedPalliative care consultation and advance directive completed eleven days before adjuvant cycle 1

Interventions

InterventionStatusGuideline
Urgent neuro-oncology consultation within one week, together with neurosurgery, to review the brain MRI with her and plan diagnosis and treatment if it shows a tumorcompletedGL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021
New progressive focal neurologic symptoms are imaged promptly: MRI of the brain with and without contrast within 24 hours, with same-day emergency care if she worsens, has a seizure, vomits or becomes drowsy; blood count, chemistry and A1c; no driving until the cause is knowncompletedGL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021
Dexamethasone only for edema causing symptoms, at the lowest effective dose (4 mg twice a day), with famotidine and glucose checks, and tapered off as soon as possible after surgerycompletedGL-EANO-GLIOMA-2021, GL-NCCN-CNS-2026
CT of the chest, abdomen and pelvis to exclude another primary; functional MRI with tractography; awake craniotomy with language and motor mapping for maximal safe resection; MRI within 48 hours; integrated WHO CNS5 diagnosis with IDH1 R132H immunostaining and IDH1 and IDH2 sequencing, ATRX, TERT promoter, EGFR, chromosome 7 and 10, CDKN2A, histone H3, BRAF and MGMT promoter methylationcompletedGL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021, GL-WHO-CNS5-2021
No antiseizure prophylaxis, because she has had no seizure; seizure first aid taught to her and her household; levetiracetam if a seizure occurscompletedGL-SNO-EANO-AED-2021, GL-EANO-GLIOMA-2021
Venous thromboembolism: mechanical and then low-molecular-weight heparin prophylaxis in hospital after surgery; no routine prophylaxis at home; she is taught the signs of leg clot and pulmonary embolism and to report them the same daycompletedGL-ASCO-VTE-2023, GL-NCCN-CNS-2026
Radiotherapy 60 Gy in 30 fractions with temozolomide 75 mg/m2 daily, then six cycles of temozolomide 150 to 200 mg/m2 on days 1 to 5 of each 28-day cycle; Pneumocystis prophylaxis during concurrent treatment and while lymphopenia lasts; antiemetic before each dose; blood count weekly during chemoradiation and on day 22 of each adjuvant cycle; liver tests at baseline, mid-cycle 1 and before each cycle; MRI four weeks after radiotherapy and then every two to three months, read by RANO 2.0; clinical trial screeningcompletedGL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021, GL-STUPP-2005, GL-HEGI-2005, GL-TMZ-LABEL, GL-ASCO-SNO-2022, GL-RANO-2023
Tumor-treating fields with adjuvant temozolomide, worn at least 18 hours a day, with scalp checks and skin carecompletedGL-EF14-2017, GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021
Falls and mobility from the first visit: home safety review, fall plan, physical therapy assessment once the treatment plan is set, and a check at every visit of strength in both legs, since new right-sided weakness adds to a left leg weakened by polio in childhood; watch for new weakness, fatigue or pain that could signal post-polio syndromecompletedGL-EFNS-PPS-2006, GL-EANO-GLIOMA-2021
Early palliative care alongside cancer treatment: symptoms, coping, goals and advance care planning, and support for the people she choosescompletedGL-ASCO-PALL-2024, GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021
Distress and depression screening at each visit, plain explanations with written information, and help to keep working as long as she wishes; she decides who receives informationcompletedGL-USPSTF-DEP-2023, GL-CMID-2026, GL-NCCN-CNS-2026

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Norwood A. Wilma Rudolph National Women's History Museum other
SRC-0002 Wilma Rudolph: Olympic Sprinter (U.S. Olympic & Paralympic Hall of Fame) U.S. Olympic & Paralympic Museum other
SRC-0003 Lovett BL. Wilma Rudolph (1940-1994) and the TSU Tigerbelles (Tennessee Encyclopedia) Tennessee Historical Society other
SRC-0004 Rudolph, Wilma (1940-1994). Women in World History: A Biographical Encyclopedia Gale, via Encyclopedia.com other
SRC-0005 Wilma Rudolph (Olympedia athlete profile) Olympedia (OlyMADMen) other
SRC-0006 Former Olympic sprinter Wilma Rudolph dies at 54 Deseret News other
SRC-0007 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the urgency of imaging for new focal symptoms, the steroid dose and taper, the decision against seizure prophylaxis, the WHO CNS5 integrated diagnosis, the Stupp protocol doses and monitoring, the tumor-treating fields discussion, the RANO 2.0 reading of the first post-treatment MRI, and the fall plan for a polio survivor.
provenance reviewnot_startedRecent-death rule: only what she made public, what was reported during her life, and obituaries and reference accounts: the National Women's History Museum, the U.S. Olympic & Paralympic Museum, the Tennessee Encyclopedia, Women in World History, Olympedia and the Deseret News obituary. The type and treatment of her brain cancer were never made public; everything clinical is synthetic.
safe messaging reviewnot_startedNo mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail. No relative is named in the modern episode, and no health fact or decision is attributed to any real person.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.